PMID- 32354200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Apr 28
TI  - Immunomodulatory Strategies Targeting Dendritic Cells to Improve Corneal Graft 
      Survival.
LID - 10.3390/jcm9051280 [doi]
LID - 1280
AB  - Even though the cornea is regarded as an immune-privileged tissue, 
      transplantation always comes with the risk of rejection due to mismatches between 
      donor and recipient. It is common sense that an alternative to corticosteroids as 
      the current gold standard for treatment of corneal transplantation is needed. 
      Since blood and lymphatic vessels have been identified as a severe risk factor 
      for corneal allograft survival, much research has focused on vessel regression or 
      inhibition of hem- and lymphangiogenesis in general. However, lymphatic vessels 
      have been identified as required for the inflammation's resolution. Therefore, 
      targeting other players of corneal engraftment could reveal new therapeutic 
      strategies. The establishment of a tolerogenic microenvironment at the graft site 
      would leave the recipient with the ability to manage pathogenic conditions 
      independent from transplantation. Dendritic cells (DCs) as the central player of 
      the immune system represent a target that allows the induction of tolerogenic 
      mechanisms by many different strategies. These strategies are reviewed in this 
      article with regard to their success in corneal transplantation.
FAU - Schonberg, Alfrun
AU  - Schonberg A
AD  - Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, 
      University of Cologne, 50937 Cologne, Germany.
FAU - Hamdorf, Matthias
AU  - Hamdorf M
AD  - Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, 
      University of Cologne, 50937 Cologne, Germany.
FAU - Bock, Felix
AU  - Bock F
AD  - Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, 
      University of Cologne, 50937 Cologne, Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50937 
      Cologne, Germany.
LA  - eng
GR  - BO4489/1-2/Deutsche Forschungsgemeinschaft/
GR  - BO4489/3-1/Deutsche Forschungsgemeinschaft/
PT  - Journal Article
PT  - Review
DEP - 20200428
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7287922
OTO - NOTNLM
OT  - Tregs
OT  - cornea transplantation
OT  - graft rejection
OT  - hemangiogenesis
OT  - immunomodulation
OT  - lymphangiogenesis
OT  - tolDCs
OT  - tolerance
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/02 06:00
MHDA- 2020/05/02 06:01
PMCR- 2020/04/28
CRDT- 2020/05/02 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/05/02 06:01 [medline]
PHST- 2020/04/28 00:00 [pmc-release]
AID - jcm9051280 [pii]
AID - jcm-09-01280 [pii]
AID - 10.3390/jcm9051280 [doi]
PST - epublish
SO  - J Clin Med. 2020 Apr 28;9(5):1280. doi: 10.3390/jcm9051280.